Toggle navigation
Home
Feed
Channels
Profile
Home
Feed
Channels
Profile
Medspoke's Talks
Medspoke
Medspoke
BJU International
Published September 25, 2026
Trial design drives outcomes: harmonising efficacy across BCG-unresponsive bladder carcinoma in s...
September 26, 2026
Medspoke
Medspoke
Journal of Clinical Oncology (JCO)
Published September 25, 2026
00:00
--:--
Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma:...
September 26, 2026
Share
Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS.
https://www.medspoke.co/channel_journal?id=686&tap_id=14452
Copy Link
Email
X
Bluesky
WhatsApp
LinkedIn
Facebook
Reddit
Medspoke
Medspoke
The Lancet Oncology
Published September 25, 2026
Balancing benefits, costs, and harms: policy implications of expanding cancer susceptibility test...
September 26, 2026
Why are you reporting this TALK?
